Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 240 participants.

Also called NCT04984577

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Nanjing Yoko Biomedical Co., Ltd. (from the registry)
Registry
  • NCT NCT04984577
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT04984577. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-15 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Compound Edaravone Injection-Low dose
Intervention (Drug)
Compound Edaravone Injection-High dose
Intervention (Drug)
Edaravone Injection
Intervention (Drug)
Placebo injection
Lead sponsor
Nanjing Yoko Biomedical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04984577
Content hash
a318af92b7cf4d50436295657216b3d187abf8e17245b3ddce88f438f875a07d